EVERSYS
The two companies have agreed that the Italian De’Longhi Group acquires 40% of the Swiss Eversys Group, to include a two-way option whereby the remaining 60% would be transferred to De’Longhi within the next two to four years.
Eversys SA, located in Ardon (VS), specialises in the engineering, manufacturing and international commercialisation of fully automatic espresso machines, designed for the professional Horeca market. The company, founded in 2009, achieved a turnover of 17.3m CHF in 2016 with 51 employees.
The Italian De’Longhi Group is a leading stock listed manufacturer of household appliance products and is the global market leader in the segment of coffee machines for the home. In 2016 the group achieved a turnover of €1.85bn and employs over 7,100 people in multiple countries.
With the investment in Eversys, De’Longhi takes the first step into the professional espresso coffee market, with a focus on the fully automatic machines segment.
“Eversys brings a wealth of technology, a management team with proven experience in the sector and the ambition to become a leading player in the global professional coffee market. This partnership is also driven by the technological, industrial and distribution synergies, which De’Longhi is able to assure” says Fabio De’Longhi, Vice-Chairman and CEO of the De’Longhi Group.
“For Eversys the partnership with De’Longhi creates a significant potential of synergies, which will contribute to accelerate and secure our ambitious development plans. In addition, it offers the midterm possibility for the founders and current shareholders to resolve their succession strategy” says Martin Strehl, Chairman and Delegate of the Board of Eversys.
Eversys will continue to operate as a strategically separate entity, led by the previous management team and remaining located in the Region of the Valais, in Switzerland.
The closing of the transaction is expected before mid-July 2017.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170413005800/en/
Contact:
William Murray Communications
Louise Tabor
louise@williammurray.co.uk
07769905408
or
Chelsey
Osborne
chelsey@williammurray.co.uk
0208
256 1360
Interviews available on request
www.eversys.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EV Group Strengthens Its European Presence With the Acquisition of Cornelius Polska22.1.2026 13:19:00 CET | Press release
Eigenmann & Veronelli Group (“EV Group”), a leading distributor and manufacturer of specialty chemicals and food ingredients, has signed an agreement to acquire the majority shareholding in Cornelius Polska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122961168/en/ Photographed (left to right): Ludovico Balbo di Vinadio, Shareholder and Deputy Chairman, EV Group; Piotr Wasilewski, General Manager, Cornelius Polska Sp. z. o. o.; Cristina Colombo, Chief Financial Officer, EV Group; Dr Neville Prior, Group Chairman, Cornelius Group plc; Gabriele Bonomi, Chief Executive Officer, EV Group Established in Poland in 2007 and headquartered in Warsaw, Poland, Cornelius Polska is a well‑established distributor of specialty chemicals, serving as a key partner to international suppliers, and a broad and diverse customer base. With operations firmly rooted in Poland, the company is active in the beauty & personal care, food, and sev
Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES22.1.2026 13:00:00 CET | Press release
Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrollment of the first patients in the STARS DAPT (ST-Segment Elevation Myocardial InfArction treated with a Polymer-Free Sirolimus-based NanocarrieR Eluting Stent and a P2Y12 inhibitor-based Single Antiplatelet Strategy after a Short Dual Antiplatelet Therapy versus conventional Dual AntiPlatelet Therapy) randomized controlled trial. This trial marks a significant milestone in evaluating the breakthrough technology of polymer free drug eluting stent (DES) for the treatment of STEMI patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121338054/en/ Concept Medical announces first patient enrollment in the STARS DAPT randomized clinical trial evaluating Abluminus™ NP polymer-free DES The first four patients were enrolled by (Professor Barbara Stähli and her team at the University Hospital of Zurich in Swi
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing22.1.2026 12:00:00 CET | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and remediation of filing delinquencies. Under the Panel’s decision, SINOVAC must, on or before May 11, 2026, demonstrate compliance with Nasdaq Listing Rule 5250(c)(1) and Listing Rule 5250(c)(2) by completing filings of its annual report for the year ended December 31, 2024 on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of year 2025 on Form 6-K. As disclosed on January 4, 2026, the Company has engaged Zhonghua Certified Public Accountants LLP (“Zhonghua”) as its independent registered public accounting firm. SINOVAC is working diligently with Zhonghua to complete the required audit and t
Sisvel Launches Wi-Fi Multimode Patent Pool22.1.2026 12:00:00 CET | Press release
Ten patent owners establish licensing solution covering Wi-Fi 6 and Wi-Fi 7 standards Sisvel has launched a groundbreaking Wi-Fi Multimode patent pool offering access to standard essential patents owned by 10 Wi-Fi 6 and Wi-Fi 7 technology leaders. As the successor to Sisvel’s highly successful Wi-Fi 6 patent pool – which, over a three-year period, closed agreements with nearly 40 companies, including Acer, Netgear, Cisco and HP – the new programme offers an efficient way to access essential Wi-Fi rights for years to come. The 10 founding patent owners in the Wi-Fi Multimode programme are Huawei, KPN, Mitsubishi Electric, Orange, Panasonic, Philips, Aegis 11 SA (a Sisvel affiliate), SK Telecom, Wilus and ZTE. In addition, Sony Group Corporation has taken a licence under the Wi-Fi Multimode programme. This early agreement with a sophisticated and globally recognised Wi-Fi leader and implementer underlines the pool’s strong value proposition and the efforts made by Sisvel to engage with
Otto Group Enables AI-driven Intelligent Robot Coordination With the Digital Twin Developed by Roboverse Reply22.1.2026 11:52:00 CET | Press release
Reply [EXM, STAR: REY] is supporting the global retailer Otto Group in implementing a central, AI-driven virtual control system for intelligent robotic orchestration. Developed as part of a strategic collaboration between Otto Group, Reply, and NVIDIA, the "Robotic Coordination Layer" enables the training, simulation, and orchestration of autonomous mobile robots and stationary systems, accelerating delivery times and enhancing service levels This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122331989/en/ This initiative with the Otto Group and NVIDIA underscores Roboverse Reply’s role as an implementation partner for AI-powered robotics and Physical AI in logistics. At the centre is a high-fidelity digital twin, serving as a precise replica of the warehouse environment and accurately representing the positions, movements, and interactions of all robotic systems. Developed thanks to Roboverse Reply’s expertise in robotic int
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom